At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
XTX202drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating XTX202 for Advanced Solid Tumor. Completed, enrolled 95 participants across 15 sites.
Detailed Summary
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartJan 2022
Primary CompletionMar 2025
Study CompletionMar 2025
TodayJul 2026
First PostedSep 22, 2021
Enrollment StartJan 18, 2022
Primary CompletionMar 22, 2025
Study CompletionMar 25, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.8 years ago
Interventions
XTX202drug
XTX202 Monotherapy